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ENGLISH VERSION: RESULTS OF A 3 MONTH TREATMENT  
WITH METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS 
ASSOCIATED WITH ISCHAEMIC HEART DISEASE*  
Lavrenko A. V., Rasdin M. S., Savchenko L.G.,, Mamontova T. V.,  Vesnina L. E., Kaidashev I. P. 
MSEI of Ukraine «Ukrainian Medical Stomatological Academy«, Poltava 
The aim of the research was to investigate the effectiveness of mid-term inclusion of Metformin in the complex therapy 
in patients with diabetes type 2 in combination with IHD for the rational justification of timing, doses of the drug. Mate-
rials and methods. 52 man suffering from diabetes type 2 on background of ischaemic heart disease have been ob-
served. An effect of included Metformin at mid-term rate (3 months) was estimated. The blood rates are observed (total 
cholesterol (TC), HDL-cholesterol, total lipids (TL), triglycerides (TG), β-lipoproteins, glycated hemoglobin, C-peptide) 
and anti inflammatory markers (IL-1β, IL-6, IL-8 and TNF-α). Results. In patients with diabetes type 2 on background of 
ischaemic heart disease during 3 months under the action of metformin significant decrease in body weight, waist cir-
cumference, BMI, concentration of total cholesterol, C-peptide and insulin resistance index and cytokines level IL-1β, IL-
6 and TNF-α were observed. Conclusion. The obtained results indicate the purpose of Metformin prescription in patients 
with diabetes type 2 and IHD in the continuation of 3 months; it is an effective and safe method of treatment of such 
patients.  
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The question about the effectiveness of Metformin in 
patients with type 2 diabetes mellitus on background of 
ischaemic heart disease, and pharmacodynamic effects 
continues to be discussed [1,3,4]. In previous work, we 
have described the efficacy and safety of Metformin as 
initial insulin therapy for diabetes type 2 in combination 
with ischaemic heart disease after 1 month of treatment 
with Metformin. The clinical trials, anthropometric data, 
carbohydrate and lipid metabolism and systemic inflam-
mation have been studied. The results showed improve-
ment in clinical condition, reduction of body weight, lower 
total cholesterol, low-density lipoproteins, glycated he-
moglobin, C-peptide, index of insulin resistance, markers 
of systemic inflammation, increased levels of high-density 
lipoproteins [2]. 
The aim of this work was to study the effectiveness 
of mid-term inclusion of Metformin in the complex therapy 
of patients with diabetes type 2 in combination with IHD 
for the rational justification of timing, doses of the drug. 
Materials and methods 
52 men aged 45-65 years were included in the clinical 
study, they suffered from ischaemic heart disease in 
combination with diabetes type 2. The study was con-
ducted in the period from 2008 to 2010 on the basis of 
the 1st City Clinical Hospital, Poltava and Research Insti-
tute of the genetic and immunological basis for the de-
velopment of pathology and pharmacogenetics of the 
Ukrainian medical stomatological academy. Before be-
ginning the study an approval from the Commission of 
bioethics was obtained. 
Patients were diagnosed with diabetes type 2 and 
IHD according to WHO criteria. 
All patients underwent a screening examination for 
verification of diabetes type 2 diagnoses and ischaemic 
heart disease before the clinical study. There were 52 
selected patients after screening who took a standard 
complex drug therapy within a month: acetylsalicylic acid 
75 mg 1 time a day at night, bisoprolol 5-10 mg 1 time a 
day, atorvastin 10 mg 1 time a day, nitroglycerin 0.5 mg 
(angina). All patients have got an advice about diet and 
lifestyle changes. 
During the first day of the study all patients were tak-
ing blood samples and performed clinical examination. 
After that, in the combined therapy Metformin at a dose 
of 500 mg 2 times a day was included (Siofor, Berlin-
Chemie), i.e. firstly a drug therapy by oral hypoglycemic 
drug was assigned. A second survey was carried out af-
ter 1 month and 3 months. Anthropometric indicators 
(height, weight, calculated the body mass index (BMI) 
were evaluated. All patients were examined clinically in-
cluding: blood analysis, urine analysis, blood sugar 
analysis, urine sugar analysis, biochemical blood analy-
sis, total cholesterol, α-cholesterol, triglycerides, lipopro-
tein, total lipids, ultrasound of kidney, ultrasound of the 
heart, ECG. All methods were routine and aimed at veri-
fying and determining the severity of the main disease, 
and identification of comorbidity. 
The character of changes of the current disease was 
assessed by functional class of exertional angina, sever-
ity of hypertension, the severity of heart failure.  
The study of changes in lipid metabolism in patients 
was conducted by means of biochemical methods deter-
mining the concentrations of total cholesterol, cholesterol 
high density lipoprotein (HDL), total lipids, triglycerides, 
lipoproteins in blood serum using reagent kits (Bio-La-
Test, Czech Republic). 
Carbohydrate metabolism was investigated by deter-
mining the concentration of glucose and glycosylating 
hemoglobin (HbA1c) in the blood of patients. Determina-
tion of glycosylated hemoglobin was performed using 
"Glycosylamines hemoglobin" (Bio-La-Test, Czech Re-
public). 
The concentration of C-peptide was determined in se-
rum by ELISA using test system (DRG International, Inc. 
USA). 
For the insulin resistance estimation are used our pro-
posed index of insulin resistance calculated by the formula:  
Concentration of  С-peptide x concentration of HbA1c , 
9,71 
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 which in healthy people should be about 1. 
The study of the immune and inflammatory response 
was performed by determination of the major regulator of 
interleukin - 1 (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8). 
The reagent kits are used for determination of the quantita-
tive determination of human interleukin (IL-1 beta, IL-6, IL-8) 
in human biological fluids and in culture substrate (Russia, 
IL-1 beta ELISA-BEST, JSC "Vector-Best ). 
For estimation of the organism immune status a proin-
flammatory cytokine has been studied. It is an important mo-
lecular mediator of intercellular interactions - alpha TNF (tu-
mor necrosis factor). Quantitative levels of TNF alpha were 
determined using a set of reagents for the quantitative de-
termination of human alpha TNF in biological fluids of hu-
man and cultural environments (Russia, alpha TNF-ELISA-
the BEST, JSC "Vector-best"). 
Statistical analysis of results were performed using the 
standard STATISTICA 6.0 (StatSoft, USA) with the calcula-
tion of the arithmetic mean, standard deviation, probability of 
the obtained results of T-test for the pair bonded and inde-
pendent variables (t). For selected indicators, the reliability of 
differences was calculated by nonparametric methods of 
Wilcoxon and Van der Waerden. The difference frequency 
was estimated by calculating χ2. 
Research results and discussion 
In clinical research, we have formed a group of patients 
suffering from diabetes type 2 on background of ischaemic 
heart disease, which has criteria of WHO and ISPAD. 
Table 1 
Peculiarities of the course of diabetes type 2 in patients with ischaemic heart disease in the dynamics of treatment 
Angina Arterial hypertension Chronic heart failure Group  
(n=52) FC ІІ FC ІІI  Easy art. Medium heavy art. NYHA І NYHA ІІ 
Before treatment Metformin 47 5 14 38 22 30 
After 1 month of therapy 
with Metformin 49 3 24 28 31 21 
After 3 months of therapy 
with Metformin 51 1 28 24 37 15 
χ2 Pearson, df=1 (for 1 
month) 
χ2 = 0,135; 
р = 0,713 
χ2 = 3,359; 
р = 0,067 
χ2 = 2,462; 
р = 0,117 
χ2 Pearson, df=1 (for 3 
months) 
χ2 = 1,592; 
р = 0,207 
χ2 = 6,750; 
р = 0,009 
χ2 = 7,678; 
р = 0,006 
 
As can be seen from the data oftable. 1, the patients 
with diabetes type 2 on background of ischaemic heart 
disease mostly with stable angina of second functional 
class were represented. The patients with moderate arte-
rial hypertension and 2-stage heart failure are dominated.  
These data confirm that included patients with 
ischemic heart disease who have previously experienced 
such an important syndrome as hypertension. 
The duration of CHD in the group was from 1 to 10 
years, obesity from 1 to 5 years, hypertension from 1 to 
10 years.  
As shown in table. 1, among patients prevailed with 
angina FC II, mild arterial hypertension - 14, moderate - 
38, chronic heart failure of first degree at 22, and II - 30 
patients. The inclusion of Metformin in the complex ther-
apy of IHD has resulted in improved clinical course of the 
disease during the first month of Metformin. But after 3 
months there was a reliable decrease in functional class 
of exertional angina, and a tendency to decrease blood 
pressure levels and stages of chronic heart failure. 
Table 2  
Anthropometric data from patients with ischaemic heart disease and diabetes mellitus type 2 in the dynamics of treatment 
Patients  
(n=52) Weight, kg Height, cm Waist circumference, cm The body mass index, c.u. 
Before treatment with 
Metformin 112,1±7,4 118,2±7,1 35,4±4,1 
After 1 month of therapy 
with Metformin 111,7±6,2* 116,6±5,3* 34,1±3,6* 
After 3 months of therapy 
with Metformin 110,8±4,7* 
176,0±6,55 
113,6±3,9* 33,8±2,9* 
* the reliability of differences between the groups before treatment (p is >0,05) 
After 3 months of Metformin therapy as follows from ta-
ble 2, anthropometric indicators after 3 months of treatment 
with Metformin did not differ from the respective figures in 1 
month and were significantly lower than before treatmen. 
Table 3 
Lipid metabolism in patients with type 2 diabetes mellitus on the background of IHD in the dynamics of treatment 
Patients  
(n=52) 
Total cholesterol, 
mmol/l 
The HDL choles-
terol, mol/l 
Triglycerides  
mmol/l 
The atherogenic 
index The LDL-C, mol/l 
Before with treatment Met-
formin 6,58±0,27 1,30±0,04 2,14±0,19* 4,07±1,18 4,31±0,42 
After 1 month of therapy 
with Metformin   5,04±0,21* 1,41±0,03* 1,53±0,11* 2,57±1,08* 2,97±0,20* 
After 3 months of therapy 
with Metformin 4,53±0,19** 1,40±0,01* 1,33±0,09* 2,12±1,05** 2,77±0,16** 
Note: here and after: * - p <0,05 compared to before treatment,  
** - p <0,05 in comparison with indicators 1 month 
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After 3 months of Metformin therapy, reduction in total 
cholesterol due to HPNP and atherogenic index. contin-
ued (compared with 1-month therapy results) 
Table 4 
Indicators of carbohydrate metabolism, cytokines and cellular factors in patients with metabolic syndrome in the dynamics of treatment 
Patients  
(n=52) 
Glycosylated  
hemoglobin,  
µmol of 
fructose/g HB 
with A1 
C-peptide,  
ng/ml Index IR IL-1β, pg/ml 
IL-6, 
pg/ml IL-8, pg/ml TNF-α, pg/ml 
Before the Met-
formin prescription 5,23±0,75 13,63±1,52 7,35±0,88 17,92 ± 1,8 41,4±12,8 35,7±8,6 24,92±3,1 
After 1 month of 
therapy with Met-
formin 
4,84±0,45* 8,14±1,74* 4,10±0,82* 7,67±1,8* 19,4±1,8* 18,52±2,2* 18,52±1,9* 
After 3 months of 
therapy with Met-
formin 
4,10±0,27** 8,01±1,57* 4,03±0,72* 7,07±1,4** 19,1±1,5* 18,15±1,9* 18,42±1,8* 
Note: here and after: * - p <0,05 compared with the rates before treatment,  
 ** - p <0,05 in comparison with indicators in a 1 month 
As can be seen from the data presented (table. 4), af-
ter 3 months of treatment with Metformin the level of 
HbA1c and IL1β has decreased. Other indicators re-
mained at the level achieved after treatment during 1 
month. 
Our results showed that stable process of diabetes 
type 2 for patients with coronary artery disease treated 
using modern complex drug therapy is characterized by 
predominantly overweight, moderate disturbances of lipid 
metabolism and presence of insulin resistance with pro-
nounced activity of systemic inflammation. These data 
are grounds for the inclusion of Metform in standard 
complex therapy. 
As can be seen from the table. 2, short-term use of 
Metformin for the last 1 month has caused a significant 
decrease in body weight, waist circumference and BMI 
(р<0,05), but after 3 months has confirmed the reduction 
of anthropometric indicators. Tendencies towards lower 
levels of total cholesterol have been observed too. How-
ever, reliable applications performance characteristic of 
lipid metabolism for 1 month have not been identified. But 
after 3 months there was a tendency to normal lipid me-
tabolism. Similarly, it was not observed a significant de-
crease of the level of indicators characterizing the level of 
insulin resistance. However, the index of insulin resis-
tance was decreased by 45,3%. 
Very important was a registered significant decrease 
in the concentrations of IL-1β and IL-6 in serum (table.4) 
to 8.69±6,94 and 9.33±9,84 pg/ml, respectively . The 
level of IL-8 was decreased significantly due to individual 
variability parameters after treatment. The concentration 
of TNF-α was not changed significantly. 
The results show that systemic inflammation plays an 
important role in the development of diabetes type 2 and 
IHD. Especially important in practical terms, there is evi-
dence that modern integrated medical therapy of is-
chaemic heart disease, including nitrates, acetylsalicylic 
acid, β-blocker and a statin, does not lead to sufficient 
reduction of the level of systemic inflammation, and in 
patients with diabetes type 2 and reduce the insulin resis-
tance. 
Data concerning the concentration of proinflammatory 
cytokines in patients with diabetes type 2 on background 
of ischaemic heart disease co-ordinate with the results of 
M. Mamedov [5] derived from patients with different clini-
cal IHD and various risk factors. The authors rightly con-
clude that the presence of systemic inflammation in pa-
tients destabilization of the atherosclerotic process and 
its increasing in unstable (progressive) angina process. 
As you know, as a primary molecular mechanism of ac-
tion of Metformin is considered the inhibition of complex 1 
of the respiratory chain, which leads to decreased pro-
duction of ATP, the increase in the ratio of 
AMP/ADP/ATP and inhibition of gluconeogenesis [11]. 
Our findings emphasize the simultaneous reduction in the 
activity of immune system cells that produce cytokines 
inflammation, which can also be a result of the above 
process, but plays an independent role as a factor in the 
reduction of insulin resistance. 
Conclusions: after 3 months of treatment with Met-
formin patients with diabetes type 2 on background of 
ischaemic heart disease, compared with the results ob-
tained after 1 month of treatment displayed: 
1. Patients have a tendency towards improvements 
of clinical rates, reduction in the functional class of exer-
tional angina, the severity of heart failure, blood pressure, 
and also saved the achieved reduction of body mass in-
dex. 
2. The further improvement in lipid metabolism was 
noted: the reduction of total cholesterol, triglycerides, and 
atherogenic index.  
3. Saving of a level of glycated hemoglobin C-pep-
tide, index of insulin resistance and systemic inflamma-
tion was achieved in 1 month,. 
4. Obtained results indicate that Metformin pre-
scription for the patients with diabetes type 2 and IHD 
during 3 months is an effective and safe method of 
treatment of such patients. 
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